This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Issa, S. Articles by Schweikert, H.-U. Search for Related Content PubMed PubMed Citation Articles by Issa, S. Articles by Schweikert, H.-U.

Human Osteoblast-Like Cells Express Predominantly Steroid 5-Reductase Type 1

Department of Internal Medicine, University of Bonn (S.I., D.S., M.F., H.U.S.), Bonn, Germany; Department of Orthopedics, St. Petrus Krankenhaus (L.W.), 53113 Bonn, Germany; Department of Pathology, University of Freiburg (H.E.S.), 79002 Freiburg, Germany; and Department of Molecular Genetics, University of Texas Southwestern Medical Center (D.W.R.), Dallas, Texas 75390-9046

Address all correspondence and requests for reprints to: Hans-Udo Schweikert, M.D., Endocrinology, Department of Internal Medicine, University of Bonn, Wilhelmstrasse 35-37, 53111 Bonn, Germany.

Abstract

In previous studies we established that human bone and human osteoblast-like cells (hOB cells) cultured from bone express 5-reductase (5-R) activity, as demonstrated by the conversion of testosterone and androstenedione to their corresponding 5-reduced metabolites, 5-dihydrotestosterone (DHT) and 5-androstanedione. Two 5-R isozymes (types 1 and 2) have been identified in various tissues. As their nature in bone is unknown, we investigated which isozymes were expressed in first passage hOB cells cultured from bone specimens obtained from six donors (five women and one man). For comparison, 5-reductase isozyme expression in genital skin fibroblasts cultured from foreskin of three males was determined. Pharmacological and biochemical studies using selective inhibitors of the 5-R isozymes were performed, and gene expression was assessed by RT-PCR. In hOB cells, LY191704, a potent nonsteroidal selective inhibitor of 5-R type 1, and the 4-azasteroid 17ß-(N,N,-diethyl-carbamoyl)-4-methyl-4-aza-5-androstan-3-one (a dual inhibitor of 5-R types 1 and 2) inhibited 5-R activity with a 50% inhibitory concentration (IC₅₀) of approximately 4 nM. Finasteride, a selective inhibitor of 5-R type 2, blocked 5-R activity with an IC₅₀ of approximately 60 nM. The IC₅₀ of progesterone, a physiological substrate for 5-R, was approximately 200 nM. In genital skin fibroblasts, LY191704 inhibited 5-R with an IC₅₀ of more than 5000 nM, whereas finasteride and 17ß-(N,N,-diethyl-carbamoyl)-4-methyl-4-aza-5-androstan-3-one effectively inhibited 5-R with IC₅₀ of approximately 4 nM. Experiments to determine 5-reductase activity in homogenates of hOB cells as a function of pH showed very low activity at pH 5.5, but a broad shoulder of activity from pH 6.0–9.0, which was not inhibited by finasteride, but was nearly completely blocked by LY191704. RT-PCR revealed that 5-R type 1 and 2 mRNAs were expressed in both bone and genital skin fibroblasts. Based on our pharmacological and biochemical studies, it appears that 5-R activity in hOB cells is catalyzed predominantly by the type 1 rather than the type 2 isozyme. This expression pattern is in contrast to that in genital skin fibroblasts, where the activity of the type 2 isozyme prevails. As in most androgen target tissues DHT is biologically more active as an androgen than testosterone, DHT is formed in bone by 5-R type 1 action from circulating testosterone, and bone cells also express the androgen receptor, local DHT production may play a physiological role in human bone homeostasis.

This article has been cited by other articles:

				A. E Lemus, J. Enriquez, A. Hernandez, R. Santillan, and G. Perez-Palacios Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells J. Endocrinol., February 1, 2009; 200(2): 199 - 206. [Abstract] [Full Text] [PDF]

				S. J. Jacobsen, T. C. Cheetham, R. Haque, J. M. Shi, and R. K. Loo Association Between 5-{alpha} Reductase Inhibition and Risk of Hip Fracture JAMA, October 8, 2008; 300(14): 1660 - 1664. [Abstract] [Full Text] [PDF]

				J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites J. Endocrinol., June 1, 2007; 193(3): 493 - 504. [Abstract] [Full Text] [PDF]

				M. T Zarrabeitia, J. L Hernandez, C. Valero, A. Zarrabeitia, J. A Amado, J. Gonzalez-Macias, and J. A Riancho Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density Eur. J. Endocrinol., January 1, 2007; 156(1): 117 - 122. [Abstract] [Full Text] [PDF]

				A. M. Pino, J. M. Rodriguez, S. Rios, P. Astudillo, L. Leiva, G. Seitz, M. Fernandez, and J P. Rodriguez Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin J. Endocrinol., December 1, 2006; 191(3): 715 - 725. [Abstract] [Full Text] [PDF]

				V. Sobel, B. Schwartz, Y.-S. Zhu, J. J. Cordero, and J. Imperato-McGinley Bone Mineral Density in the Complete Androgen Insensitivity and 5{alpha}-Reductase-2 Deficiency Syndromes J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3017 - 3023. [Abstract] [Full Text] [PDF]

				M. Muir, G. Romalo, L. Wolf, W. Elger, and H.-U. Schweikert Estrone Sulfate Is a Major Source of Local Estrogen Formation in Human Bone J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4685 - 4692. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]

				J. Compston Local Biosynthesis of Sex Steroids in Bone J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5398 - 5400. [Full Text] [PDF]